Cumulative exposure to high-dose angiotensin receptor blockers was associated with excess risk for cancer, according to a meta-regression analysis published in PLOS One.“About 200 million people are treated with an angiotensin receptor blocker (ARB) globally. This analysis shows that when 200 million people are exposed to daily high doses of an ARB for 4.7 years, 1.7 million excess cancers
The trial-level analysis suggests a dose-response relationship between exposure to angiotensin receptor blockers and the risk for cancer, reawakening previous questions on this issue.